Ruxolitinib cream monotherapy leads to clinically significant improvements in facial and body repigmentation in teens and adults with nonsegmental vitiligo, new research shows.

According to late-breaking findings presented at the American Academy of Dermatology annual meeting last month, the Janus kinase (JAK) inhibitor was well-tolerated with no serious safety signals versus vehicle.

“These results are extremely encouraging and highlight the clinical potential of ruxolitinib cream for patients with vitiligo,” said abstract co-author and US dermatologist Dr David Rosmarin, from the Tufts Medical Center in Boston.

“[There’s] potential that when we add in, for instance, phototherapy or other treatments that could be synergistic, we’ll see even bigger responses.”